eravacycline Side Effects
Also known as: Xerava
Analysis of 205 adverse event reports submitted to the FDA from 2019 to 2025.
Total Reports
205
Death-Related
33
16.1% of reports
Hospitalizations
57
27.8% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 33 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 13 |
| DRUG INEFFECTIVE | 10 |
| OFF LABEL USE | 9 |
| ACUTE RESPIRATORY DISTRESS SYNDROME | 6 |
| THROMBOCYTOPENIA | 5 |
| BLOOD FIBRINOGEN DECREASED | 4 |
| HYPERTRANSAMINASAEMIA | 4 |
| LACTIC ACIDOSIS | 4 |
| SHOCK | 4 |
| BLASTOMYCOSIS | 3 |
| CONDITION AGGRAVATED | 3 |
| DRUG INTOLERANCE | 3 |
| ENTEROCOCCAL INFECTION | 3 |
| MYCOBACTERIUM ABSCESSUS INFECTION | 3 |
| PNEUMONITIS | 3 |
| SEPSIS | 3 |
| SEPTIC SHOCK | 3 |
| DISSEMINATED BLASTOMYCOSIS | 2 |
| PULMONARY BLASTOMYCOSIS | 2 |
| ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED | 1 |
Reactions in Hospitalization Reports
Top reactions in 57 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| OFF LABEL USE | 19 |
| DRUG INEFFECTIVE | 11 |
| BLOOD FIBRINOGEN DECREASED | 9 |
| HYPERTRANSAMINASAEMIA | 8 |
| LACTIC ACIDOSIS | 8 |
| THROMBOCYTOPENIA | 8 |
| ACUTE RESPIRATORY DISTRESS SYNDROME | 6 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 6 |
| BLASTOMYCOSIS | 3 |
| BLOOD BILIRUBIN INCREASED | 3 |
| DRUG INTOLERANCE | 3 |
| ENTEROCOCCAL INFECTION | 3 |
| NAUSEA | 3 |
| PNEUMONITIS | 3 |
| PROTHROMBIN TIME PROLONGED | 3 |
| SEPSIS | 3 |
| BILIRUBIN CONJUGATED INCREASED | 2 |
| COAGULOPATHY | 2 |
| CONDITION AGGRAVATED | 2 |
| DIARRHOEA | 2 |
Nearby — Related Medications
What the FAERS Data Reveals About eravacycline Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 205 voluntary reports linked to eravacycline and its brand equivalents (Xerava), spanning 2019 through 2025. Of those, 33 (16.1%) listed death as an outcome and 57 (27.8%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 35% were female and 65% male; age distribution skews toward 45-64, with 45 reports in that bracket. The single most reported reaction is off label use with 62 submissions, followed by drug ineffective and blood fibrinogen decreased.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.